INKmune
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Key Facts
About INmune Bio
INmune Bio is a clinical-stage biotech focused on precisely modulating the innate immune system to treat Alzheimer's disease and cancer. Its strategy centers on two distinct platforms: XPro1595, a dominant-negative TNF inhibitor that neutralizes only the soluble form driving pathology, and INKmune, an in vivo NK cell primer. The company is advancing multiple Phase 2 trials, with a development philosophy anchored in patient biology and clinically relevant metrics.
View full company profileAbout INmune Bio
INmune Bio is a clinical-stage biotech focused on precisely modulating the innate immune system to treat Alzheimer's disease and cancer. Its strategy centers on two distinct platforms: XPro1595, a dominant-negative TNF inhibitor that neutralizes only the soluble form driving pathology, and INKmune, an in vivo NK cell primer. The company is advancing multiple Phase 2 trials, with a development philosophy anchored in patient biology and clinically relevant metrics.
View full company profileTherapeutic Areas
Other Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Tomivosertib | eFFECTOR Therapeutics | Phase 2 |
| Gedatolisib + Darolutamide | Celcuity | Phase 1b/3 |
| SNP-101 (estimated) | SmartNuclide Biopharma | Phase 1 |
| AB001 (²¹²Pb-NG001) | ARTBIO | Phase 1/2 |
| AB-3028 | Arsenal Biosciences | IND-Enabling |
| PRO CAR-201A | PromiCell | Phase 1 |
| PRO CAR-202 | PromiCell | Preclinical |
| FG-3246 | Kyntra Bio | Phase 2 |
| PROVENGE (sipuleucel-T) | Dendreon | Approved |
| RP12146 | Rhizen Pharmaceuticals | Phase 1b |
| Monoclonal Antibody (undisclosed) | MetaCurUm Biotech | Preclinical |
| ModraDoc006/r | Modra Pharmaceuticals | Phase 2b |